Memorial Sloan Kettering Cancer Center
2019 ASH Review on Combinations or Sequences of Targeted Agents in CLL: Ibrutinib + Venetoclax for the 1st-Line Treatment - Should MRD Status at EOT Be Driving Treatment Decisions?
By
Cleveland Clinic's 20th Annual ASH Review
FEATURING
Anthony R. Mato
By
Cleveland Clinic's 20th Annual ASH Review
FEATURING
Anthony R. Mato
Login to view comments.
Click here to Login